Advanced search
Publication Cover
Molecular and Cellular Biology Volume 27, 2007 - Issue 15
Submit an article Journal homepage
58
Views
88
CrossRef citations to date
0
Altmetric
Article

Hypoxia-Inducible Factor Linked to Differential Kidney Cancer Risk Seen with Type 2A and Type 2B VHL Mutations

Lianjie Li1 Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts02115;2 Howard Hughes Medical Institute, Chevy Chase, Maryland20815
,
Liang Zhang3 Department of Urology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts02115
,
Xiaoping Zhang3 Department of Urology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts02115
,
Qin Yan1 Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts02115;2 Howard Hughes Medical Institute, Chevy Chase, Maryland20815
,
Yoji Andrew Minamishima1 Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts02115
,
Aria F. Olumi3 Department of Urology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts02115
,
Mao Mao4 Rosetta Inpharmatics LLC, Seattle, Washington98109
,
Steven Bartz4 Rosetta Inpharmatics LLC, Seattle, Washington98109
&
William G. Kaelin Jr.1 Department of Medical Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts02115;2 Howard Hughes Medical Institute, Chevy Chase, Maryland20815Correspondence[email protected]
 show all
Pages 5381-5392 | Received 15 Feb 2007, Accepted 17 May 2007, Published online: 27 Mar 2023

Citations (88)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (5)

Elshad Hasanov & Eric Jonasch. (2021) MK-6482 as a potential treatment for von Hippel-Lindau disease-associated clear cell renal cell carcinoma. Expert Opinion on Investigational Drugs 30:5, pages 495-504.
Read now
Jordan M. Thompson, Jaime Landman & Olga V. Razorenova. (2020) Targeting the RhoGTPase/ROCK pathway for the treatment of VHL/HIF pathway-driven cancers. Small GTPases 11:1, pages 32-38.
Read now
Betty Gardie, Melanie J Percy, David Hoogewijs, Rasheduzzaman Chowdhury, Celeste Bento, Patrick R Arsenault, Stéphane Richard, Helena Almeida, Joanne Ewing, Frédéric Lambert, Mary Frances McMullin, Christopher J Schofield & Frank S Lee. (2014) The role of PHD2 mutations in the pathogenesis of erythrocytosis. Hypoxia 2, pages 71-90.
Read now
W Kimryn Rathmell & Shufen Chen. (2008) VHL inactivation in renal cell carcinoma: implications for diagnosis, prognosis and treatment. Expert Review of Anticancer Therapy 8:1, pages 63-73.
Read now
Mireille Khacho, Karim Mekhail, Karine Pilon-Larose, Josianne Payette & Stephen Lee. (2008) Cancer-Causing Mutations in a Novel Transcription-Dependent Nuclear Export Motif of VHL Abrogate Oxygen-Dependent Degradation of Hypoxia-Inducible Factor. Molecular and Cellular Biology 28:1, pages 302-314.
Read now

Articles from other publishers (83)

Ravneet Chhabra, Jennifer Guergues, Jessica Wohlfahrt, Stephanie Rockfield, Pamela Espinoza Gonzalez, Shanon Rego, Margaret A. Park, Anders E. Berglund, Stanley M. StevensJr.Jr. & Meera Nanjundan. (2023) Deregulated expression of the 14q32 miRNA cluster in clear cell renal cancer cells. Frontiers in Oncology 13.
Crossref
Alessandra Cinque, Roberto Minnei, Matteo Floris & Francesco Trevisani. (2022) The Clinical and Molecular Features in the VHL Renal Cancers; Close or Distant Relatives with Sporadic Clear Cell Renal Cell Carcinoma?. Cancers 14:21, pages 5352.
Crossref
William G. KaelinJr.Jr.. (2022) Von Hippel–Lindau disease: insights into oxygen sensing, protein degradation, and cancer. Journal of Clinical Investigation 132:18.
Crossref
Michael Ohh, Cassandra C Taber, Fraser G Ferens & Daniel Tarade. (2022) Hypoxia-inducible factor underlies von Hippel-Lindau disease stigmata. eLife 11.
Crossref
Elshad Hasanov, Isabel Pimentel, Mara Cruellas, Mark A. Lewis, Eric Jonasch & Judith Balmaña. (2022) Current Systemic Treatments for the Hereditary Cancer Syndromes: Drug Development in Light of Genomic Defects. American Society of Clinical Oncology Educational Book:42, pages 808-824.
Crossref
Agata Swiatkowska. (2022) p53 and Its Isoforms in Renal Cell Carcinoma—Do They Matter?. Biomedicines 10:6, pages 1330.
Crossref
Petra Hudler & Mojca Urbancic. (2022) The Role of VHL in the Development of von Hippel-Lindau Disease and Erythrocytosis. Genes 13:2, pages 362.
Crossref
Xuechun Wang, Jin Hu, Yihao Fang, Yanbin Fu, Bing Liu, Chao Zhang, Shan Feng & Xin Lu. (2022) Multi-Omics Profiling to Assess Signaling Changes upon VHL Restoration and Identify Putative VHL Substrates in Clear Cell Renal Cell Carcinoma Cell Lines. Cells 11:3, pages 472.
Crossref
Mohamed Zardab, Konstantinos Stasinos, Richard P. Grose & Hemant M. Kocher. (2022) The Obscure Potential of AHNAK2. Cancers 14:3, pages 528.
Crossref
Jun Zhou, Yasamin Dabiri, Rodrigo A. Gama-Brambila, Shahrouz Ghafoory, Mukaddes Altinbay, Arianeb Mehrabi, Mohammad Golriz, Biljana Blagojevic, Stefanie Reuter, Kang Han, Anna Seidel, Ivan Đikić, Stefan Wölfl & Xinlai Cheng. (2022) pVHL-mediated SMAD3 degradation suppresses TGF-β signaling. Journal of Cell Biology 221:1.
Crossref
Alessandro Larcher, Isaline Rowe, Federico Belladelli, Giuseppe Fallara, Daniele Raggi, Andrea Necchi, Francesco Montorsi, Umberto Capitanio & Andrea Salonia. (2022) Von Hippel–Lindau disease-associated renal cell carcinoma: a call to action. Current Opinion in Urology 32:1, pages 31-39.
Crossref
Olivia Lombardi & David Robert Mole. 2021. Biomarkers and Bioanalysis Overview. Biomarkers and Bioanalysis Overview.
Toni K. Choueiri & William G. KaelinJrJr. (2020) Targeting the HIF2–VEGF axis in renal cell carcinoma. Nature Medicine 26:10, pages 1519-1530.
Crossref
Adam Kinnaird, Aristeidis E. Boukouris, Bruno Saleme, Peter Dromparis, Sotirios D. Zervopoulos, Vikram Gurtu, Gopinath Sutendra & Evangelos D. Michelakis. (2020) Interaction with p53 explains a pro-proliferative function for VHL in cancer. Journal of Molecular Medicine 98:9, pages 1269-1278.
Crossref
Lianxin Hu, Haibiao Xie, Xijuan Liu, Frances Potjewyd, Lindsey I. James, Emily M. Wilkerson, Laura E. Herring, Ling Xie, Xian Chen, Johnny Castillo Cabrera, Kai Hong, Chengheng Liao, Xianming Tan, Albert S. Baldwin, Kan Gong & Qing Zhang. (2020) TBK1 Is a Synthetic Lethal Target in Cancer with VHL Loss . Cancer Discovery 10:3, pages 460-475.
Crossref
Sarah V. Faull, Andy M. C. Lau, Chloe Martens, Zainab Ahdash, Kjetil Hansen, Hugo Yebenes, Carla Schmidt, Fabienne Beuron, Nora B. Cronin, Edward P. Morris & Argyris Politis. (2019) Structural basis of Cullin 2 RING E3 ligase regulation by the COP9 signalosome. Nature Communications 10:1.
Crossref
Heike Miess, Beatrice Dankworth, Arvin M. Gouw, Mathias Rosenfeldt, Werner Schmitz, Ming Jiang, Becky Saunders, Michael Howell, Julian Downward, Dean W. Felsher, Barrie Peck & Almut Schulze. (2018) The glutathione redox system is essential to prevent ferroptosis caused by impaired lipid metabolism in clear cell renal cell carcinoma. Oncogene 37:40, pages 5435-5450.
Crossref
M. Nazhif Zaini, Saroor A. Patel, Saiful E. Syafruddin, Paulo Rodrigues & Sakari Vanharanta. (2018) Endogenous HIF2A reporter systems for high-throughput functional screening. Scientific Reports 8:1.
Crossref
Jing Zhang, Tao Wu, Jeremy Simon, Mamoru Takada, Ryoichi SaitoCheng FanXian-De Liu, Eric Jonasch, Ling XieXian ChenXiaosai Yao, Bin Tean Teh, Patrick TanXingnan Zheng, Mingjie Li, Cortney LawrenceJie Fan, Jiang Geng, Xijuan LiuLianxin HuJun WangChengheng LiaoKai HongGiada ZurloJoel S. Parker, J. Todd Auman, Charles M. Perou, W. Kimryn Rathmell, William Y. KimMarc W. Kirschner, William G. KaelinJr.Jr., Albert S. Baldwin & Qing Zhang. (2018) VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma. Science 361:6399, pages 290-295.
Crossref
Olga Astapova, Anindita Biswas, Alessandra DiMauro, Jacob Moalem & Stephen R. Hammes. (2018) Bilateral Pheochromocytomas in a Patient with Y175C Von Hippel-Lindau Mutation. Case Reports in Endocrinology 2018, pages 1-4.
Crossref
Paulo Rodrigues, Saroor A. Patel, Louise Harewood, Ioana Olan, Erika Vojtasova, Saiful E. Syafruddin, M. Nazhif Zaini, Emma K. Richardson, Johanna Burge, Anne Y. Warren, Grant D. Stewart, Kourosh Saeb-Parsy, Shamith A. Samarajiwa & Sakari Vanharanta. (2018) NF-κB–Dependent Lymphoid Enhancer Co-option Promotes Renal Carcinoma Metastasis. Cancer Discovery 8:7, pages 850-865.
Crossref
Zhengwen He, Lu Xia, Zhiyong Deng, Aojie Lian, Zhengmao Hu & Bin Li. (2018) Identification of a VHL gene mutation in a Chinese family with Von Hippel‑Lindau syndrome. Molecular Medicine Reports.
Crossref
Stefano Motta, Claudia Minici, Dario Corrada, Laura Bonati & Alessandro Pandini. (2018) Ligand-induced perturbation of the HIF-2α:ARNT dimer dynamics. PLOS Computational Biology 14:2, pages e1006021.
Crossref
D Tarade & M Ohh. (2017) The HIF and other quandaries in VHL disease. Oncogene 37:2, pages 139-147.
Crossref
K Zhang, S-M Myllymäki, P Gao, R Devarajan, V Kytölä, M Nykter, G-H Wei & A Manninen. (2017) Oncogenic K-Ras upregulates ITGA6 expression via FOSL1 to induce anoikis resistance and synergizes with αV-Class integrins to promote EMT. Oncogene 36:41, pages 5681-5694.
Crossref
Wendi Sun, Hiroyuki Kato, Shojiro Kitajima, Kian Leong Lee, Katarina Gradin, Takashi Okamoto & Lorenz Poellinger. (2017) Interaction between von Hippel-Lindau Protein and Fatty Acid Synthase Modulates Hypoxia Target Gene Expression. Scientific Reports 7:1.
Crossref
Jianping GuoAbhishek A. ChakrabortyPengda LiuWenjian GanXingnan ZhengHiroyuki InuzukaBin WangJinfang ZhangLinli ZhangMin YuanJesse NovakJin Q. ChengAlex TokerSabina SignorettiQing ZhangJohn M. AsaraWilliam G. KaelinJr.Jr. & Wenyi Wei. (2016) pVHL suppresses kinase activity of Akt in a proline-hydroxylation–dependent manner. Science 353:6302, pages 929-932.
Crossref
Adam Kinnaird, Peter Dromparis, Bruno Saleme, Vikram Gurtu, Kristalee Watson, Roxane Paulin, Sotirios Zervopoulos, Trevor Stenson, Gopinath Sutendra, Desmond B. Pink, Katia Carmine-Simmen, Ronald Moore, John D Lewis & Evangelos D. Michelakis. (2016) Metabolic Modulation of Clear-cell Renal Cell Carcinoma with Dichloroacetate, an Inhibitor of Pyruvate Dehydrogenase Kinase. European Urology 69:4, pages 734-744.
Crossref
Johannes Schödel, Steffen Grampp, Eamonn R. Maher, Holger Moch, Peter J. Ratcliffe, Paul Russo & David R. Mole. (2016) Hypoxia, Hypoxia-inducible Transcription Factors, and Renal Cancer. European Urology 69:4, pages 646-657.
Crossref
Hyejin Cho & William G. Kaelin. (2016) Targeting HIF2 in Clear Cell Renal Cell Carcinoma. Cold Spring Harbor Symposia on Quantitative Biology 81, pages 113-121.
Crossref
Miriam de Fatima Brasil Engelman & Gustavo Gonçalves Engelman. 2016. Biomarkers in Kidney Disease. Biomarkers in Kidney Disease 991 1013 .
Dalei Wu, Nalini Potluri, Jingping Lu, Youngchang Kim & Fraydoon Rastinejad. (2015) Structural integration in hypoxia-inducible factors. Nature 524:7565, pages 303-308.
Crossref
Mei Yee Koh, Vuvi Nguyen, Robert LemosJrJr, Bryant G. Darnay, Galina Kiriakova, Mena Abdelmelek, Thai H. Ho, Jose Karam, Federico A. Monzon, Eric Jonasch & Garth Powis. (2015) Hypoxia-Induced SUMOylation of E3 Ligase HAF Determines Specific Activation of HIF2 in Clear-Cell Renal Cell Carcinoma. Cancer Research 75:2, pages 316-329.
Crossref
Lucy Gossage, Tim Eisen & Eamonn R. Maher. (2014) VHL, the story of a tumour suppressor gene. Nature Reviews Cancer 15:1, pages 55-64.
Crossref
Miriam de Fatima Brasil Engelman & Gustavo Gonçalves Engelman. 2015. Biomarkers in Kidney Disease. Biomarkers in Kidney Disease 1 23 .
William G. KaelinJr.Jr.. 2015. Kidney Cancer. Kidney Cancer 31 57 .
Lucy Gossage. 2015. Renal Cell Carcinoma. Renal Cell Carcinoma 57 110 .
Norma Masson & Peter J Ratcliffe. (2014) Hypoxia signaling pathways in cancer metabolism: the importance of co-selecting interconnected physiological pathways. Cancer & Metabolism 2:1.
Crossref
Saadia A Aziz, Joshua A Sznol, Laurence Albiges, Christopher Zito, Lucia B Jilaveanu, Robert L Camp, Bernard Escudier & Harriet M Kluger. (2014) Microvessel area as a predictor of sorafenib response in metastatic renal cell carcinoma. Cancer Cell International 14:1.
Crossref
Sophie Couvé, Charline Ladroue, Elodie Laine, Karène Mahtouk, Justine Guégan, Sophie Gad, Hélène Le Jeune, Marion Le Gentil, Gregory Nuel, William Y. Kim, Bernard Lecomte, Jean-Christophe Pagès, Christine Collin, Françoise Lasne, Patrick R. Benusiglio, Brigitte Bressac-de Paillerets, Jean Feunteun, Vladimir Lazar, Anne-Paule Gimenez-Roqueplo, Nathalie M. Mazure, Philippe Dessen, Luba Tchertanov, David R. Mole, William Kaelin, Peter Ratcliffe, Stéphane Richard & Betty Gardie. (2014) Genetic Evidence of a Precisely Tuned Dysregulation in the Hypoxia Signaling Pathway during Oncogenesis. Cancer Research 74:22, pages 6554-6564.
Crossref
Nickie C. Chan, Willem den Besten, Michael J. Sweredoski, Sonja Hess, Raymond J. Deshaies & David C. Chan. (2014) Degradation of the Deubiquitinating Enzyme USP33 Is Mediated by p97 and the Ubiquitin Ligase HERC2. Journal of Biological Chemistry 289:28, pages 19789-19798.
Crossref
Julie Mathieu, Wenyu Zhou, Yalan Xing, Henrik Sperber, Amy Ferreccio, Zsuzsa Agoston, Kavitha T. Kuppusamy, Randall T. Moon & Hannele Ruohola-Baker. (2014) Hypoxia-Inducible Factors Have Distinct and Stage-Specific Roles during Reprogramming of Human Cells to Pluripotency. Cell Stem Cell 14:5, pages 592-605.
Crossref
David Vindrieux, Guillaume Devailly, Arnaud Augert, Benjamin Le Calvé, Mylène Ferrand, Pascal Pigny, Léa Payen, Gérard Lambeau, Michael Perrais, Sébastien Aubert, Hélène Simonnet, Robert Dante & David Bernard. (2014) Repression of PLA2R1 by c-MYC and HIF-2alpha promotes cancer growth. Oncotarget 5:4, pages 1004-1013.
Crossref
Naomi B. Haas & Katherine L. Nathanson. (2014) Hereditary Kidney Cancer Syndromes. Advances in Chronic Kidney Disease 21:1, pages 81-90.
Crossref
Christina M. Ferrer & Mauricio J. Reginato. 2014. Cancer Genomics and Proteomics. Cancer Genomics and Proteomics 73 88 .
Lianjie Li, Chuan Shen, Eijiro Nakamura, Kiyohiro Ando, Sabina Signoretti, Rameen Beroukhim, Glenn S. Cowley, Patrick Lizotte, Ella Liberzon, Steven Bair, David E. Root, Pablo Tamayo, Aviad Tsherniak, Su-Chun Cheng, Barbara Tabak, Anders Jacobsen, A. Ari Hakimi, Nikolaus Schultz, Giovanni Ciriello, Chris Sander, James J. Hsieh & William G. KaelinJr.Jr.. (2013) SQSTM1 Is a Pathogenic Target of 5q Copy Number Gains in Kidney Cancer. Cancer Cell 24:6, pages 738-750.
Crossref
Ting Zhang, Xiaohua Niu, Lili Liao, Eun-Ah Cho & Haifeng Yang. (2013) The Contributions of HIF-Target Genes to Tumor Growth in RCC. PLoS ONE 8:11, pages e80544.
Crossref
I. Jochmanova, C. Yang, Z. Zhuang & K. Pacak. (2013) Hypoxia-Inducible Factor Signaling in Pheochromocytoma: Turning the Rudder in the Right Direction. JNCI Journal of the National Cancer Institute 105:17, pages 1270-1283.
Crossref
Peter J. Ratcliffe. (2013) Oxygen sensing and hypoxia signalling pathways in animals: the implications of physiology for cancer. The Journal of Physiology 591:8, pages 2027-2042.
Crossref
Paulo A. Gameiro, Juanjuan Yang, Ana M. Metelo, Rocio Pérez-Carro, Rania Baker, Zongwei Wang, Alexandra Arreola, W. Kimryn Rathmell, Aria Olumi, Pilar López-Larrubia, Gregory Stephanopoulos & Othon Iliopoulos. (2013) In Vivo HIF-Mediated Reductive Carboxylation Is Regulated by Citrate Levels and Sensitizes VHL-Deficient Cells to Glutamine Deprivation. Cell Metabolism 17:3, pages 372-385.
Crossref
Chuan Shen & William G. KaelinJr.Jr.. (2013) The VHL/HIF axis in clear cell renal carcinoma. Seminars in Cancer Biology 23:1, pages 18-25.
Crossref
Sakari Vanharanta, Weiping Shu, Fabienne Brenet, A Ari Hakimi, Adriana Heguy, Agnes Viale, Victor E Reuter, James J-D Hsieh, Joseph M Scandura & Joan Massagué. (2012) Epigenetic expansion of VHL-HIF signal output drives multiorgan metastasis in renal cancer. Nature Medicine 19:1, pages 50-56.
Crossref
Chunzhang Yang, Kristin Huntoon, Alexander Ksendzovsky, Zhengping Zhuang & Russell R. Lonser. (2013) Proteostasis Modulators Prolong Missense VHL Protein Activity and Halt Tumor Progression. Cell Reports 3:1, pages 52-59.
Crossref
George M. Yousef, Nicole M. A. White & Andrew H. Girgis. 2013. Cancer Genomics. Cancer Genomics 185 217 .
Masafumi Kato, Sohei Yamamoto, Masashi Takano, Osamu Matsubara & Kenichi Furuya. (2012) Aberrant Expression of the Mammalian Target of Rapamycin, Hypoxia-inducible Factor-1α, and Glucose Transporter 1 in the Development of Ovarian Clear-cell Adenocarcinoma. International Journal of Gynecological Pathology 31:3, pages 254-263.
Crossref
William G. KaelinJr.Jr.. 2012. Kidney Cancer. Kidney Cancer 29 46 .
William G. KaelinJr.Jr.. 2012. Renal Cell Carcinoma. Renal Cell Carcinoma 27 47 .
Chuan Shen, Rameen Beroukhim, Steven E. Schumacher, Jing Zhou, Michelle Chang, Sabina Signoretti & William G. KaelinJrJr. (2011) Genetic and Functional Studies Implicate HIF1 α as a 14q Kidney Cancer Suppressor Gene . Cancer Discovery 1:3, pages 222-235.
Crossref
Lianjie Li & William G. KaelinJr.Jr.. (2011) New Insights into the Biology of Renal Cell Carcinoma. Hematology/Oncology Clinics of North America 25:4, pages 667-686.
Crossref
AD Sorrell, S Lee, C Stolle, J Ellenhorn, A Grix, WG KaelinJrJr & JN Weitzel. (2011) Clinical and functional properties of novel VHL mutation (X214L) consistent with Type 2A phenotype and low risk of renal cell carcinoma . Clinical Genetics 79:6, pages 539-545.
Crossref
Lauren P. Blair, Jian Cao, Mike Ran Zou, Joyce Sayegh & Qin Yan. (2011) Epigenetic Regulation by Lysine Demethylase 5 (KDM5) Enzymes in Cancer. Cancers 3:1, pages 1383-1404.
Crossref
Claudio R. Thoma, Alexandre Matov, Katrin L. Gutbrodt, Christian R. Hoerner, Zlatko Smole, Wilhelm Krek & Gaudenz Danuser. (2010) Quantitative image analysis identifies pVHL as a key regulator of microtubule dynamic instability. Journal of Cell Biology 190:6, pages 991-1003.
Crossref
Lucy Gossage & Tim Eisen. (2010) Alterations in VHL as potential biomarkers in renal-cell carcinoma. Nature Reviews Clinical Oncology 7:5, pages 277-288.
Crossref
María J. Calzada. (2010) Von Hippel-Lindau syndrome: molecular mechanisms of the disease. Clinical and Translational Oncology 12:3, pages 160-165.
Crossref
Tsz-fung F. Chow, Youssef M. Youssef, Evi Lianidou, Alexander D. Romaschin, R. John Honey, Robert Stewart, Kenneth T. Pace & George M. Yousef. (2010) Differential expression profiling of microRNAs and their potential involvement in renal cell carcinoma pathogenesis. Clinical Biochemistry 43:1-2, pages 150-158.
Crossref
Harry A. Drabkin & Robert M. Gemmill. 2010. 39 56 .
Olga V. Razorenova & Amato J. Giaccia. 2010. The Tumor Microenvironment. The Tumor Microenvironment 43 58 .
Valentina Bangiyeva, Ava Rosenbloom, Ashlynn E Alexander, Bella Isanova, Timothy Popko & Alan R Schoenfeld. (2009) Differences in regulation of tight junctions and cell morphology between VHL mutations from disease subtypes. BMC Cancer 9:1.
Crossref
Claudio R. Thoma, Alberto Toso, Katrin L. Gutbrodt, Sabina P. Reggi, Ian J. Frew, Peter Schraml, Alexander Hergovich, Holger Moch, Patrick Meraldi & Wilhelm Krek. (2009) VHL loss causes spindle misorientation and chromosome instability. Nature Cell Biology 11:8, pages 994-1001.
Crossref
William G. KaelinJrJr. (2009) Treatment of kidney cancer. Cancer 115:S10, pages 2262-2272.
Crossref
Patrick J. PollardPeter J. Ratcliffe. (2009) Puzzling Patterns of Predisposition. Science 324:5924, pages 192-194.
Crossref
C M Lee, M M Hickey, C A Sanford, C G McGuire, C L Cowey, M C Simon & W K Rathmell. (2009) VHL Type 2B gene mutation moderates HIF dosage in vitro and in vivo. Oncogene 28:14, pages 1694-1705.
Crossref
Hong Xin, Chunyan Zhang, Andreas Herrmann, Yan Du, Robert Figlin & Hua Yu. (2009) Sunitinib Inhibition of Stat3 Induces Renal Cell Carcinoma Tumor Cell Apoptosis and Reduces Immunosuppressive Cells. Cancer Research 69:6, pages 2506-2513.
Crossref
C. Lance Cowey & W. Kimryn Rathmell. (2009) VHL gene mutations in renal cell carcinoma: Role as a biomarker of disease outcome and drug efficacy. Current Oncology Reports 11:2, pages 94-101.
Crossref
Kimberly Stegmaier & William R. Sellers. 2009. Oncology of Infancy and Childhood. Oncology of Infancy and Childhood 57 98 .
Kathryn E. Hacker, Caroline Martz Lee & W. Kimryn Rathmell. (2008) VHL Type 2B Mutations Retain VBC Complex Form and Function. PLoS ONE 3:11, pages e3801.
Crossref
William G. Kaelin Jr. (2008) The von Hippel–Lindau tumour suppressor protein: O2 sensing and cancer. Nature Reviews Cancer 8:11, pages 865-873.
Crossref
Jin Zhang, Yiran Huang, Jiahua Pan, Dongming Liu, Lixin Zhou, Wei Xue, Qi Chen, Baijun Dong & Hanqing Xuan. (2008) Germline mutations in the von Hippel–Lindau disease (VHL) gene in mainland Chinese families. Journal of Cancer Research and Clinical Oncology 134:11, pages 1211-1218.
Crossref
Archana Bommi-ReddyIngrid AlmecigaJacqueline Sawyer, Christoph Geisen, Wenliang Li, Ed Harlow, William G. KaelinJrJr & Dorre A. Grueneberg. (2008) Kinase requirements in human cells: III. Altered kinase requirements in VHL −/− cancer cells detected in a pilot synthetic lethal screen . Proceedings of the National Academy of Sciences 105:43, pages 16484-16489.
Crossref
C. Ricketts, E. R. Woodward, P. Killick, M. R. Morris, D. Astuti, F. Latif & E. R. Maher. (2008) Germline SDHB Mutations and Familial Renal Cell Carcinoma. JNCI Journal of the National Cancer Institute 100:17, pages 1260-1262.
Crossref
S A Patel & M C Simon. (2008) Biology of hypoxia-inducible factor-2α in development and disease. Cell Death & Differentiation 15:4, pages 628-634.
Crossref
Arthur P. Young, Susanne Schlisio, Yoji Andrew Minamishima, Qing Zhang, Lianjie Li, Chiara Grisanzio, Sabina Signoretti & William G. KaelinJrJr. (2008) VHL loss actuates a HIF-independent senescence programme mediated by Rb and p400. Nature Cell Biology 10:3, pages 361-369.
Crossref
Andrew M Roberts & Michael Ohh. (2008) Beyond the hypoxia-inducible factor-centric tumour suppressor model of von Hippel-Lindau. Current Opinion in Oncology 20:1, pages 83-89.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.